SCHEMBL3965404

SCHEMBL3965404

COC(=O)c1ccc2cc(-c3nc(Cl)ncc3Cl)sc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.49
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
PDGFRB P09619 3/20 0.40
KDR P35968 3/20 0.40
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HTT P42858 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
MEN1 O00255 1/20 0.39
TNF P01375 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3962466 0.90 HDAC1 (0.48) HDAC1PIK3CAPIK3CBPIK3CGPI4KB
SCHEMBL3964580 0.86 HDAC6 (0.44) HDAC1PIK3CAPI4KBKDRNPC1
SCHEMBL3968825 0.77 BTK (0.39) HDAC1NPC1RAB9AKMT2AKDM4E
SCHEMBL3965558 0.76 PKM (0.49) SMN1; SMN2KMT2AHTTHPGD
SCHEMBL3970210 0.76 NPC1 (0.41) HDAC1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3964101 0.76 FGFR1 (0.46)
SCHEMBL3968816 0.76 HDAC6 (0.43) HDAC1NPC1RAB9ASMN1; SMN2HDAC6
SCHEMBL5385077 0.76 MAP2K4 (0.47) KDRNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3963487 0.75 RPS6KA5 (0.32) KDR
SCHEMBL25224406 0.74 HDAC1 (0.64) HDAC1PIK3CAPIK3CBPIK3CGPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG HDAC1 1093/4885PIK3CA 170/4885PIK3CB 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.